Mesna

Mesna
Systematic (IUPAC) name
sodium 2-sulfanylethanesulfonate
Clinical data
AHFS/Drugs.com monograph
Pregnancy cat. B1 (Au), B (U.S.)
Legal status S4 (Au), POM (UK), ℞-only (U.S.)
Routes Oral, intravenous
Pharmacokinetic data
Bioavailability 45–79% (Oral)
Metabolism Oxidised in circulation
Half-life 0.36–8.3 hours
Excretion Renal
Identifiers
CAS number 19767-45-4 YesY
ATC code R05CB05 V03AF01
PubChem CID 29769
ChemSpider 27663 YesY
UNII NR7O1405Q9 N
KEGG D01459 YesY
ChEMBL CHEMBL975 YesY
Chemical data
Formula C2H5NaO3S2 
Mol. mass 164.181 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Mesna (INN) (play /ˈmɛznə/) is an organosulfur compound. It is used in cancer chemotherapy involving cyclophosphamide and ifosfamide as an adjuvant. It is marketed by Baxter as Uromitexan and Mesnex. MESNA is an acronym for 2-Mercaptoethane sulfonate Na (Na being the symbol for sodium).

Contents

Uses

As a chemotherapy adjuvant

Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein.

Mesna assists to detoxify these metabolites by reaction of its sulfhydryl group with the vinyl group. It also increases urinary excretion of cysteine.

Other

Outside North America, mesna is also used as a mucolytic agent, working in the same way as acetylcysteine; it is sold for this indication as Mistabron[1] and Mistabronco.

Administration

It is administered intravenously, but oral dosing has been investigated.[2]

Mechanism

It is believed to act as an antioxidant.[3]

References

  1. ^ "Mistabron Ampoules". South African Electronic Package Inserts. August 1973. http://home.intekom.com/pharm/ucb/mistabrn.html. Retrieved 2008-08-12. 
  2. ^ Mace JR, Keohan ML, Bernardy H, et al (December 2003). "Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide". Clin. Cancer Res. 9 (16 Pt 1): 5829–34. PMID 14676103. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=14676103. 
  3. ^ Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B (March 2001). "Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure". Nephrol. Dial. Transplant. 16 (3): 542–51. doi:10.1093/ndt/16.3.542. PMID 11239029. http://ndt.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=11239029. 

External links